Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory. The company’s primary clinical focus is electrophysiology, specifically cardiac ablation procedures for the treatment of arrhythmias, utilizing proprietary Robotic Magnetic Navigation technology to control the tips of flexible interventional catheters. Key products include the Genesis RMN and GenesisX RMN Systems, the Odyssey and Synchrony & SynX information solutions, and interventional devices under the Map-iT, MAGiC, and EMAGIN brands. Stereotaxis serves hospitals and physicians globally, with clinical use documented in over 100 hospitals. The company maintains strategic partnerships with fluoroscopy system manufacturers and catheter providers, including a collaboration with Osypka AG to develop next-generation magnetic ablation catheters. Founded in 1990, Stereotaxis was formerly known as Stereotaxis, Inc. and went public in 2004.

Summarised from the company's own disclosures, fiscal year ended Mar 2026

Industry Medical Devices Homepage stereotaxis.com
Sector Healthcare IR page ir.stereotaxis.com
Tags
robotic surgery, cardiac ablation, electrophysiology, magnetic navigation, endovascular intervention, catheter technology, medical imaging, operating room systems, GenesisX RMN, Genesis RMN, Niobe, Navigant, Synchrony, SynX, Odyssey, Odyssey Cinema, MAGiC, MAGiC Sweep, EMAGIN, Map-iT, QuikCAS, Cardiodrive, Vdrive, Vdrive Duo, V-CAS, V-Loop, V-Sono, NuVizion
Press page —

Metrics

Valuation  
Market cap $ 82.397M
Market cap (USD) $ 82.397M
P/E -3.40
PEG —
P/BV 3.86
P/S 2.61
P/OCF -5.40
P/FCF -5.98
Dividend yield —
Turnover / mcap —
Returns  
ROE -221.3%
ROI -445.9%
ROIC -341.7%
Profit margin -66.8%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y No
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable No
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 11.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 20
Quality score -58.8%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Revenue 32.377M 26.918M 26.771M 28.147M 35.021M 26.63M 28.903M 29.347M 31.144M 32.164M 37.675M 35.011M 38.031M 46.562M 41.987M 54.051M 51.15M 40.365M 39.299M 27.192M 15.026M 18.817M 5.015M
Net profit -21.643M -24.045M -20.713M -18.292M -10.716M -6.646M -4.591M 116.756K -5.887M -5.287M -7.353M -5.202M -68.758M -9.238M -32.031M -19.923M -27.494M -43.886M -48.122M -45.72M -43.558M -27.257M -24.037M
Free cash flow -13.778M -8.531M -9.505M -10.793M -4.343M -3.583M -4.646M -2.812M -4.756M — — — — — — — -23.793M -30.32M -40.458M -41.289M -43.325M — —

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003
Share price 2.3 2.28 1.75 2.07 6.2 5.09 5.29 1.09 0.84 0.65 0.75 1.48 3.62 1.53 0.94 3.56 4.22 4.64 12.65 12 — — —
Price performance 12m 0.01 0.3 -0.15 -0.67 0.22 -0.04 3.87 0.29 0.3 -0.13 -0.5 -0.59 1.36 0.63 -0.74 -0.16 -0.09 -0.63 0.05 — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 4.67M 4.29M 5.02M 5.33M 3.52M 5.41M 5.09M 3.82M 3.82M 5.85M
↳ YoY growth -26.8% -8.1% +17.1% +6.1% -34.0% +53.8% -5.8% -24.9% +0.1% +52.9%
↳ 5y CAGR -15.9% -18.0% -7.9% -3.8% -11.2% +3.0% +3.5% -5.3% -6.4% +10.7%
Borrowings, current (USD) — — — — 1.19M — — — — —
Borrowings, non-current (USD) — — — — 973,252 — — — — —
Lease liabilities (USD) — — — 4.34M 2.29M 6.11M 5.86M 5.49M 6.01M 5.44M
Cash and deposits (USD) 8.5M 3.69M 10.8M 30.2M 43.9M 38.7M 8.59M 19.8M 12.2M 13.4M
Intangible assets (USD) 436,569 159,470 — — — — — — 7.36M 6.43M
Right-of-use assets (USD) — — — 4.29M 2.24M 5.73M 5.38M 4.98M 5.48M 4.91M
Net debt (borrowings + leases - cash) (USD) — — — — -39.5M — — — — —
Cash flow detail
Operating cash flow (USD) -6.56M -4.67M -2.55M -4.62M -3.51M -2.95M -8.42M -9.14M -8.5M -13.7M
Purchases of property, plant and equipment (USD) -410,184 -81,577 -265,482 -29,486 -70,896 -1.4M -2.38M -366,000 -34,000 -93,000
Change in receivables (cash effect) (USD) 1.71M 378,704 -733,856 -308,466 1.81M -1.89M 316,000 1.27M 691,000 -2.02M
Change in inventories (cash effect) (USD) -853,171 285,406 -365,142 -655,864 -1.45M -1.14M -2.91M -550,000 677,000 -1.24M
Change in payables (cash effect) (USD) 782,875 -968,909 72,259 372,737 -490,461 1.43M -169,000 218,000 758,000 -880,000
Dividends paid (cash effect) (USD) 0.00 0.00 — — 0.00 0.00 0.00 0.00 0.00 0.00
Interest paid (cash effect) (USD) -2.25M — — — — — — — — —
Share-based compensation (USD) 1.37M 768,682 560,973 1.33M 3.17M 9.36M 10.6M 10.6M 10.3M 9.85M
Operating cash flow before change in receivables (USD) -8.27M -5.05M -1.81M -4.31M -5.33M -1.06M -8.73M -10.4M -9.19M -11.7M
Free cash flow (OCF - PPE - intangibles) (USD) -6.97M -4.76M -2.81M -4.65M -3.58M -4.34M -10.8M -9.51M -8.53M -13.8M
Income detail
Research and development expense (USD) 5.49M 4.76M 8.22M 9.02M 8.14M 10.2M 10.6M 10.3M 9.76M 9.38M
↳ 5y CAGR -15.7% -10.7% +7.7% +11.8% +5.4% +13.2% +17.3% +4.6% +1.6% +2.9%
Reported Mar 20, 2018 Mar 20, 2018 Mar 15, 2019 Mar 16, 2020 May 13, 2021 Mar 10, 2022 Mar 9, 2023 Mar 8, 2024 Mar 14, 2025 Mar 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

St. Louis, November 10, 2026 (Globe Newswire) – Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today reported business updates and financial results for the third quarter ended September 30, 2026.

“Our near-term priority is to drive forward two major business model transformations,” said David Fischel, Chairman and CEO. “The first is shifting from capital systems that require long sales and construction timelines, to having a portfolio of systems that are significantly more accessible and scalable. The second is developing and commercializing a portfolio of disposable interventional catheters that enhance the value of our robots and provide a robust recurring revenue opportunity.”

“System revenue of $3 million in the quarter was up 60% compared to last year, benefiting from partial revenue recognition from the first GenesisX system in the US, the first Genesis system in China, and multiple Synchrony digital operating room systems in the US.

10/22/26 at 8:04 AM EDT

Download PDF

  • Pauls Stradiņš Clinical University Hospital installs Genesis Robotic Magnetic Navigation System, establishing the first robotic program for the treatment of cardiac arrhythmia in Latvia

  • First procedures successfully treated patients with a broad range of arrhythmia

ST. LOUIS, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that Pauls Stradiņš Clinical University Hospital in Riga, Latvia, has established the first robotic center for the treatment of cardiac arrhythmias in Latvia and has successfully treated initial patients with the Genesis Robotic Magnetic Navigation System.

“The introduction of the advanced Genesis technology at Pauls Stradiņš Clinical University Hospital reflects the hospital’s long-term commitment to developing highly specialized, modern, and patient safety focused healthcare services,” said Prof. Andrejs Ērglis, Head of the Latvian Cardiology Center at Stradiņš Hospital and Professor of Medicine at the University of Latvia. “We are proud to make this technology available to the benefit of arrhythmia patients, allowing all patients to benefit from the precision, controlled catheter movement, and safety of robotics. We particularly see value in our robotic program expanding the potential to treat complex cardiac arrhythmia.”

Pauls Stradiņš Clinical University Hospital is Latvia’s premier hospital, academic and research center, with a strong reputation in cardiology excellence. The Genesis Robotic Magnetic Navigation system introduces the benefits of robotic precision and safety to cardiac ablation, a common minimally invasive procedure to treat arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias – abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. When left untreated, arrhythmia may significantly increase the risk of stroke, heart failure, and sudden cardiac arrest.

“We are delighted to establish this new robotic electrophysiology center of excellence with Pauls Stradiņš Clinical University Hospital,” said David Fischel, Chairman and CEO of Stereotaxis. “We look forward to collaborating with the hospital and cardiology team to advance patient care in Latvia and advance clinical science that will have a global impact.”

About Stereotaxis Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Cautionary Note Regarding Forward-Looking Statements This press release includes statements that may constitute “forward-looking” statements, usually containing the words “believe”, “estimate”, “project”, “expect” or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company’s ability to manage expenses at sustainable levels, our overall liquidity and our ability to fund operations, acceptance of the Company’s products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, our ability to manage and integrate recent acquisitions, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company’s periodic and other filings with the SEC. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this press release.

Stereotaxis Contacts: David L. Fischel Chairman and Chief Executive Officer

Kimberly Peery Chief Financial Officer

314-678-6100 [email protected]

Primary Logo

10/20/26 at 7:40 AM EDT

Download PDF

ST. LOUIS, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Stereotaxis, Inc. (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced that it will release financial results for its 2026 third quarter on Tuesday, November 10, 2026 at the close of the U.S. financial markets. The Company will host a conference call and webcast at 4:30 p.m. EST that day to discuss the Company’s results and corporate developments.

| What: | Stereotaxis third quarter 2026 financial results conference call |

| When: | Tuesday, November 10, 2026, at 4:30 p.m. ET (1:30 p.m. PT) |

| Dial In Number: | To access the live call, dial 800-715-9871 (US and Canada) or 1-646-307-1963 (International) and give the participant pass code 2568629. |

| Webcast: | To access the live and replay webcast, please visit the investor relations section of Stereotaxis’ website at http://ir.stereotaxis.com/. |

| Call Replay: | A phone replay of the call will be available for one month beginning approximately four hours following the end of the call. To request access for a replay of the conference call, please click here. |

About Stereotaxis Stereotaxis, Inc. (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.

Investor Contacts: David L. Fischel Chairman and Chief Executive Officer

Kimberly Peery Chief Financial Officer

314-678-6100 [email protected]

Primary Logo

Prompts

Stereotaxis, Inc. (ticker STXS), listed in United States.